A new approach to the alzheimer's disease diagnosis with biomarkers: Description of the AD-CSF-index;Una nueva aproximación en el diagnóstico de la enfermedad de alzheimer con biomarcadores: Descripción del AD-CSF-index

Revista de Neurologia

Volumn 54, Issue 9, 2012, Pages 513-522

  Molinuevo, José L ^a,b,c   Gispert, Juan D ^b,c   Pujol, Jesús ^d   Rojas, Santiago ^e   Lladó, Albert ^a,c   Balasa, Mircea ^a,c   Antonell, Anna ^a,c   Sánchez Valle, Raquel ^a,c   Rami, Lorena ^a,c  

^a Hospital Clinic   (Spain)

^b Fundació Pasqual Maragall   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e CRC Centre d'Imatge Molecular   (Spain)

Author keywords

Alzheimer; Biomarkers; CSF; Diagnosis

Indexed keywords

AMYLOID PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ALZHEIMER DISEASE CEREBROSPINAL FLUID INDEX; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE MARKER; EPISODIC MEMORY; HUMAN; MEMORY DISORDER; RATING SCALE; SCHELTENS SCALE; SENSITIVITY AND SPECIFICITY;

EID: 84862106024     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5409.2012157     Document Type: Article

References (35)

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. Te diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.
2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA. Lancet Neurol 2007; 6: 734-746.
3. Rami L, Solé-Padullés C, Fortea J, Bosch B, Lladó A, Antonell A, et al. Applying the new research diagnostic criteria: MRI fndings and neuropsychological correlations of prodromal AD. Int J Geriatr Psychiatry 2012; 27: 127-134.
4. Valls-Pedret C, Molinuevo JL, Rami L. Diagnóstico precoz de la enfermedad de Alzheimer: fase prodrómica y preclínica. Rev Neurol 2010; 51: 471-480.
5. Berthier ML, Dávila G. Anticipando el futuro: diagnóstico de la enfermedad de Alzheimer en las fases predemencia y prodrómica. Rev Neurol 2010; 51: 449-450.
6. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2010; Dec 13. [Epub ahead of print].
7. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fuid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
8. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confrmed dementia. Neurobiol Aging 2008; 29: 1143-1159.
9. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
10. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fuid of patients with Alzheimer disease. J Am Med Assoc 2003; 289: 2094-2103.
11. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, DeDeyn P P, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999; 52: 1555-1562.
12. Vanmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winblad B, et al. Cerebrospinal fuid tau and beta-amyloid(1-42) in dementia disorders. Mech Ageing Dev 2001; 122: 2005-2011.
13. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fuid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55: 937-945.
14. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fuid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2011; Oct 31. [Epub ahead of print].
15. Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sánchez-Valle R, et al. Diferent profles of Alzheimer's disease cerebrospinal fuid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 2011; 118: 259-262.
16. Mintun MA, Larossa GN, Sheline YL, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452.
17. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fuid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349.
18. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001; 17: 101-118.
19. Jack CR, Knopman DA, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
20. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J. Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 2009; 116: 1163-1167.
21. Buschke H. Cued recall in amnesia. J Clin Neuropsychol 1984; 6: 433-440.
22. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-972.
23. Wattjes MP, Henneman WJ, Van der Flier WM, De Vries O, Träber F, Geurts JJ, et al. Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. Radiology 2009; 253: 174-183.
24. Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, Van Elk EJ, et al. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 2010; 29: 491-497.
25. Chen K, Ayutyanont N, Langbaum JB, Fleisher AS, Reschke C, Lee W, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage. 2011; 56: 52-60.
26. Consensus report of the Working Group on 'Molecular and Biochemical Markers of Alzheimer's Disease'. Te Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998; 19: 109-116.
27. Sperling RA, Johnson KA. Dementia: new criteria but no new treatments. Lancet Neurol 2012; 11: 4-5.
28. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004; 10: 1055-1063.
29. Foster NL. A new framework for the diagnosis of Alzheimer's disease. Lancet Neurol 2007; 6: 667-669.
30. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. Te Alzheimer's Association external quality control program for cerebrospinal fuid biomarkers. Alzheimers Dement 2011; 7: 386-395.
31. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the defnition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127.
32. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defning the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
33. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuro- psychological changes in 'normal' aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998; 57: 1168-1174.
34. Van Everbroeck B, Green AJ, Vanmechelen E, Vanderstichele H, Pals P, Sánchez-Valle R, et al. Phosphorylated tau in cerebrospinal fuid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2002; 73: 79-81.
35. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fuid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.